Hikma Overtakes Fresenius In US Injectables
Injectables Growth Across Regions In 2021 Accompanies Expansion Through Acquisitions
Hikma says it is now ranked second only to Pfizer in terms of US generic injectables volumes – overtaking rival Fresenius – as it continues to expand in the segment, including via recent acquisitions. Meanwhile, the firm is also laying the groundwork for a US biosimilars business.
You may also be interested in...
Hikma has debuted a pre-filled syringe formulation of succinylcholine chloride in the US, representing the first FDA-approved PFS version of the product to be launched in the market.
Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.
Hikma has added yet another Celltrion biosimilar to its marketing partnership in the Middle East and North Africa region, in the form of the Korean company’s Yuflyma higher-strength adalimumab rival to Humira.